TB-500 vs Thymosin Alpha-1
Compare the research, key figures and safety notes.
How they differ
Easy to mix up because of the shared thymosin name, but they're unrelated. TB-500 is a piece of the protein thymosin beta-4, looked at for repair, with no human dosing trial. Thymosin Alpha-1 is a separate peptide for the immune system, licensed in dozens of countries and taken 1.6 mg twice a week. They also clear very differently — days for TB-500, about two hours for Thymosin Alpha-1.
Side by side
| Measure | TB-500 | Thymosin Alpha-1 |
|---|---|---|
| Category | Recovery | Immune |
| Evidence | C · Animal or lab only | A · Human dose research |
| Route | Route not established | Subcutaneous |
| Half-life | 60 h | 2 h |
| Typical vial | 5 / 10 mg | 1.6 mg |
| Research amount | 2–5 mg | 1.6–1.6 mg |
| Common schedule | 2x per week | 2x per week |
| Cycle / break | 4–6 loading / 2–4 | — |
| Studied for | Repair and recovery | The immune system |
These amounts and schedules are figures discussed in research and community reports, shared for learning — not a recommendation and not medical advice. A step-by-step dosing schedule exists only where a human trial backs it; the evidence tier tells you which.
Decay curves, overlaid
Each line is scaled to that compound's own first dose, so the chart shows how each one builds up over time — not how the compounds' doses compare to one another, which these different molecules share no common unit for.